At the nexus of commercial success and non-obviousness
Dr. Gregory K. Bell recently testified in three successful challenges to abbreviated new drug applications (ANDA) on behalf of pharmaceutical manufacturers...
Archan Ruparel is a principal in the Life Sciences Practice at CRA. His experience includes a variety of life sciences, healthcare, general antitrust, and commercial strategy work. Mr. Ruparel has worked on reverse payment litigation, antitrust investigations and litigation, and merger clearance before the Federal Trade Commission (FTC) and Department of Justice (DOJ). His life sciences experience includes the assessment of damages in commercial disputes and intellectual property disputes; market definition and antitrust; commercially reasonable efforts cases; nutritional labelling; and policy analysis involving health technology assessment, Medicare, Medicaid, and 340B. Mr. Ruparel has also assisted healthcare companies and counsel on complex strategic questions involving economic analysis, auctions, and game theory.
Prior to joining CRA, Mr. Ruparel was with the Bureau of Economics of the FTC where he worked on studies of insurance underwriting and pharmaceutical direct-to-consumer advertising as well as investigations and litigation involving hospital mergers, telemarketing, and fair lending.